• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
      • Creating value for start-ups
      • The IP driven start-up
    • Financial Services
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • Articles
    • News
    • Events
    • Resources
    • Unified Patent Court hub
    • Beyond Brexit: European trade mark hub
    • M&C Reacts
  • Contact Us
Marks & Clerk logo
Marks & Clerk logo
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
    • Creating value for start-ups
    • The IP driven start-up
  • Financial Services
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • Articles
  • News
  • Events
  • Resources
  • Unified Patent Court hub
  • Beyond Brexit: European trade mark hub
  • M&C Reacts

FibroGen & Astellas v Akebia & Otsuka – Lord Justice Arnold returns to the Patents Court for monster six patent trial

23 June 2020
Print
Share

First published in EPLAW

Lord Justice Arnold returned to the High Court in March to hear a trial involving the validity and threatened infringement of six patents concerning the use of inhibitors (referred to as HIF-PHIs) of an enzyme called hypoxia inducible factor-prolyl hydroxylase (HIF-PH) for treating various types of anaemia and related conditions.

In a very technical and necessarily detailed judgment running to 132 pages, Lord Justice Arnold found that of all the claims in issue across all six patents, only one claim survived in an amended form and even then, that claim was not infringed.

Akebia and Otsuka sought to revoke six patents belonging to FibroGen to clear the way for their product vadadustat. Astellas, as the exclusive licensee under the six patents, brought a cross-claim for threatened infringement. Astellas had obtained a marketing authorisation for its own product, the first oral HIF-PHI product, roxadustat, in Japan in September 2019, and intends to launch the product more widely, including in the UK. (There were parallel proceedings due to be heard in the same trial involving two GSK companies and their product daprodustat, these were settled shortly before trial.)  Daprodustat and vadadustat were undergoing Phase III trials at the time of the trial.

I cannot do the decision justice in a brief headnote. It covers interesting questions of excessive claim breadth, insufficiency, claim amendment, infringement of medical use claims, quia timet infringement, infringement by equivalence and the relevance of the prosecution history. In relation to the latter two subjects, Lord Justice Arnold allowed reference to the prosecution history, commenting that this was “one of those cases referred to by Lord Neuberger in Actavis v Lilly at [88] where it would be contrary to the public interest for the contents of the prosecution file to be ignored”.

Of particular note to UK practitioners are Lord Justice Arnold’s comments on expert witnesses in patent cases and his guidance on primers:

  • He gave a stark warning to patent practitioners over how experts should be instructed and cross-examined. He referred to guidance he gave in MedImmune Ltd v Novartis Pharmaceuticals UK Ltd and a comment he made in Merck Sharp and Dome Ltd v Shionogi that “too much time is spent by cross-examiners in patent cases on ad hominem attacks that are unfair to the witness, unhelpful to the court and waste expensive time”.  He went on to re-iterate the “sequential unmasking” process that should be followed when introducing an expert witness to the prior art and the patent.
  • Lord Justice Arnold was clearly frustrated with the lack of any primer in this case involving two moderately complex areas of science. He commented that in future, “the preparation of a technical primer should be regarded as mandatory in Category 4 and 5 cases unless there are good reasons to the contrary”.

The full judgment can be seen here.



Next Story
  • Preliminary position on priority published
  • International patent insights on quantum computing
  • InterDigital v Lenovo: The latest FRAND judgment
  • Cambridge: City of Innovation - The 'beer summit' that generated a genomic revolution
  • IP protection in collaborations: "Just Do It"
More insights

Latest Insights

Chemistry
Article
- 24 March 2023

Preliminary position on priority published

As we reported in early 2022, the Enlarged Board of Appeal of the EPO are considering two pending referrals (G1/22 and G2/22) regarding the question of entitlement to priority. A hearing has now been set for 26 May 2023, and the Enlarged Board have now issued a preliminary opinion setting out the points to be discussed.
Read more
Quantum computing
Article
- 22 March 2023

International patent insights on quantum computing

The latest patent insight report from the European Patent Office (EPO) looks at the trends in patent filings for quantum computing, and has uncovered some interesting findings.
Read more
Article
- 22 March 2023

InterDigital v Lenovo: The latest FRAND judgment

On 16 March 2023, Mr Justice Mellor handed down the latest FRAND judgment: InterDigital v Lenovo. The case concerned a dispute between InterDigital and Lenovo as to the terms on which Lenovo should take a licence to InterDigital’s portfolio of patents which had been declared essential to the European Telecommunications Standard Institute (ETSI) Standards.
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Press Enquiries
  • Lexology
  • Mondaq